Meeting
2021 ASCO Annual Meeting
TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC).
Authors
Neeraj Agarwal
Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
Neeraj Agarwal , Arun Azad , Neal D. Shore , Joan Carles , Andre P. Fay , Curtis Dunshee , Lawrence Ivan Karsh , Maria Luisa Paccagnella , Nicola Di Santo , Mohamed Elmeliegy , Xun Lin , Alexander Niyazov , Akos Czibere , Karim Fizazi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT03395197
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS5089)
DOI
10.1200/JCO.2021.39.15_suppl.TPS5089
Abstract #
TPS5089
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
TALAPRO-2: a placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Neeraj Agarwal
Poster
2020 Genitourinary Cancers Symposium
TALAPRO-2: A placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Neeraj Agarwal
First Author: Charles J. Ryan
First Author: Elena Castro